PharmaLex and SwedenBIO are pleased to invite you to a Brain & Breakfast event on the 20th of February in Stockholm focusing on the EU JCA process.
The new Joint Clinical Assessment (JCA) promises big change in how products go to market. Are you ready for it? An upcoming live panel discussion — hosted by SwedenBIO and PharmaLex (Cencora) — will share what you need to know about this new regulation and how you need to prepare. If you are launching a product into Europe and Sweden, this might interest you.
Time: 20 February, 2024 at 8.30–10.00
Venue: SwedenBIO, Wallingatan 24, Stockholm
Register now!
You don’t want to miss:
- Why the JCA matters and what you can expect from the framework
- Key insights about the JCA’s process from the pilot phase
- How the JCA impact patient access for your products
- The opportunities and challenges ahead
The 𝗘𝗨 𝗝𝗖𝗔 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 as part of the 𝗘𝗨 𝗛𝗧𝗔 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻, seeking to substitute multiple country-specific clinical assessments and establish a
more streamlined and transparent single market for health technologies, will pose both a threat and an opportunity for getting innovative medicines to patients in Europe and Sweden.
SwedenBIO is the national industry organization for life science in Sweden. Our member companies develop biotechnology, diagnostics, pharmaceuticals and medical technology or are experts in areas such as business development, IP and law. We also gather financiers, incubators, science parks, regional investment promoters and many more.
